ACS Nano:铁蛋白穿越血脑屏障并靶向治疗恶性脑瘤研究获进展

2018-04-11 佚名 中科院生物物理所

近日,ACS Nano 杂志在线发表了中国科学院生物物理研究所阎锡蕴课题组与中国科学院自动化研究所田捷课题组合作完成的铁蛋白穿越血脑屏障并靶向治疗恶性脑瘤的最新研究成果。这项研究首次发现铁蛋白可以穿越血脑屏障,并可作为药物载体,实现对原位恶性脑胶质瘤的靶向和有效治疗。这是课题组继发现铁蛋白的肿瘤靶向性,并将其应用于肿瘤的体外诊断(Nature Nanotechnology,2012)、体内治疗(P

近日,ACS Nano 杂志在线发表了中国科学院生物物理研究所阎锡蕴课题组与中国科学院自动化研究所田捷课题组合作完成的铁蛋白穿越血脑屏障并靶向治疗恶性脑瘤的最新研究成果。这项研究首次发现铁蛋白可以穿越血脑屏障,并可作为药物载体,实现对原位恶性脑胶质瘤的靶向和有效治疗。这是课题组继发现铁蛋白的肿瘤靶向性,并将其应用于肿瘤的体外诊断(Nature Nanotechnology,2012)、体内治疗(PNAS,2014)及体内肿瘤多模成像(ACS Nano, 2016)之后的又一项重要成果。

血脑屏障是维持中枢神经系统稳态和保护脑部组织免受代谢产物损伤的天然屏障。然而,在保护神经系统的同时,血脑屏障也使得几乎100%的大分子药物和98%的小分子药物无法有效到达脑组织,导致大部分中枢神经系统疾病,如恶性脑瘤得不到有效的治疗。因此,对于恶性脑瘤等脑内疾病来说,目前临床治疗面临的最大挑战就是如何有效地使探针或者药物穿过血脑屏障。

受体介导的转胞吞作用是目前最有效的一种介导生物大分子药物穿越血脑屏障的途径。其中,转铁蛋白受体1(TfR1)是最具代表性的一种转胞吞作用受体。由于TfR1在脑内皮细胞和恶性脑瘤细胞上同时高表达,理论上靶向TfR1的药物既可以穿越血脑屏障,又可以富集至脑内恶性脑瘤部位。然而,由于目前大部分靶向TfR1的抗体或者配体与TfR1的亲和力过高,在穿越血脑屏障的过程中会被富集到脑内皮细胞的溶酶体中降解,导致其无法穿越血脑屏障到达病灶。

在寻找理想的TfR1配体的研究中,研究人员首次发现,铁蛋白与受体TfR1结合后,会通过脑内皮细胞的转胞吞作用穿过血脑屏障,而不会被阻断在溶酶体之中;而在恶性脑瘤细胞中,在受体TfR1的介导下,铁蛋白会被特异性地富集到溶酶体中降解,进而释放其内部装载的药物。铁蛋白的这种特性,使得其成为理想的能穿越血脑屏障并用于恶性脑瘤治疗的药物载体。在正常小鼠中,研究人员证实铁蛋白可有效穿越完整的血脑屏障;在恶性脑瘤原位移植瘤小鼠模型中,铁蛋白在穿越血脑屏障后,可以特异性地富集到肿瘤区域并抑制恶性脑瘤的生长,而在正常的脑组织无明显的富集。另外,动物安全性实验及病理学分析表明,铁蛋白可特异性地杀伤恶性脑瘤,而对正常脑组织无损伤。研究表明,铁蛋白与TfR1合适的结合亲和力、多结合位点的对称性结构以及理想的纳米尺寸效应是其既可以穿越血脑屏障又对肿瘤组织具有优异的选择性的原因。

结合本研究最新发现的铁蛋白的特性,及其易于制备、生物相容性好、药物装载量高等特点,铁蛋白可以作为一种理想的用于恶性脑瘤靶向治疗的纳米药物载体。同时,铁蛋白也为其他类型的中枢神经系统疾病,如神经退行性疾病提供了一个潜在的纳米药物载体平台。

该研究得到了国家自然科学基金重点项目、中科院先导项目、国家科技重大专项、青年人才托举工程等项目的资助。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2055907, encodeId=62a6205590e77, content=<a href='/topic/show?id=a8e1529484f' target=_blank style='color:#2F92EE;'>#恶性脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52948, encryptionId=a8e1529484f, topicName=恶性脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun May 06 14:11:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801239, encodeId=631318012398f, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Jul 30 03:11:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310059, encodeId=863e310059f6, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Sat Apr 28 09:10:16 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262340, encodeId=7cc112623404d, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275698, encodeId=065412e5698fb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279254, encodeId=637812e9254a2, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304853, encodeId=a9be304853d7, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Apr 11 19:29:11 CST 2018, time=2018-04-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2055907, encodeId=62a6205590e77, content=<a href='/topic/show?id=a8e1529484f' target=_blank style='color:#2F92EE;'>#恶性脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52948, encryptionId=a8e1529484f, topicName=恶性脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun May 06 14:11:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801239, encodeId=631318012398f, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Jul 30 03:11:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310059, encodeId=863e310059f6, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Sat Apr 28 09:10:16 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262340, encodeId=7cc112623404d, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275698, encodeId=065412e5698fb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279254, encodeId=637812e9254a2, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304853, encodeId=a9be304853d7, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Apr 11 19:29:11 CST 2018, time=2018-04-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2055907, encodeId=62a6205590e77, content=<a href='/topic/show?id=a8e1529484f' target=_blank style='color:#2F92EE;'>#恶性脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52948, encryptionId=a8e1529484f, topicName=恶性脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun May 06 14:11:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801239, encodeId=631318012398f, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Jul 30 03:11:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310059, encodeId=863e310059f6, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Sat Apr 28 09:10:16 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262340, encodeId=7cc112623404d, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275698, encodeId=065412e5698fb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279254, encodeId=637812e9254a2, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304853, encodeId=a9be304853d7, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Apr 11 19:29:11 CST 2018, time=2018-04-11, status=1, ipAttribution=)]
    2018-04-28 祝您健康

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2055907, encodeId=62a6205590e77, content=<a href='/topic/show?id=a8e1529484f' target=_blank style='color:#2F92EE;'>#恶性脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52948, encryptionId=a8e1529484f, topicName=恶性脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun May 06 14:11:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801239, encodeId=631318012398f, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Jul 30 03:11:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310059, encodeId=863e310059f6, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Sat Apr 28 09:10:16 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262340, encodeId=7cc112623404d, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275698, encodeId=065412e5698fb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279254, encodeId=637812e9254a2, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304853, encodeId=a9be304853d7, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Apr 11 19:29:11 CST 2018, time=2018-04-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2055907, encodeId=62a6205590e77, content=<a href='/topic/show?id=a8e1529484f' target=_blank style='color:#2F92EE;'>#恶性脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52948, encryptionId=a8e1529484f, topicName=恶性脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun May 06 14:11:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801239, encodeId=631318012398f, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Jul 30 03:11:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310059, encodeId=863e310059f6, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Sat Apr 28 09:10:16 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262340, encodeId=7cc112623404d, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275698, encodeId=065412e5698fb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279254, encodeId=637812e9254a2, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304853, encodeId=a9be304853d7, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Apr 11 19:29:11 CST 2018, time=2018-04-11, status=1, ipAttribution=)]
    2018-04-13 jxrzshh
  6. [GetPortalCommentsPageByObjectIdResponse(id=2055907, encodeId=62a6205590e77, content=<a href='/topic/show?id=a8e1529484f' target=_blank style='color:#2F92EE;'>#恶性脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52948, encryptionId=a8e1529484f, topicName=恶性脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun May 06 14:11:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801239, encodeId=631318012398f, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Jul 30 03:11:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310059, encodeId=863e310059f6, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Sat Apr 28 09:10:16 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262340, encodeId=7cc112623404d, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275698, encodeId=065412e5698fb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279254, encodeId=637812e9254a2, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304853, encodeId=a9be304853d7, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Apr 11 19:29:11 CST 2018, time=2018-04-11, status=1, ipAttribution=)]
    2018-04-13 yaanren
  7. [GetPortalCommentsPageByObjectIdResponse(id=2055907, encodeId=62a6205590e77, content=<a href='/topic/show?id=a8e1529484f' target=_blank style='color:#2F92EE;'>#恶性脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52948, encryptionId=a8e1529484f, topicName=恶性脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun May 06 14:11:00 CST 2018, time=2018-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801239, encodeId=631318012398f, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Jul 30 03:11:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310059, encodeId=863e310059f6, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/22/005b55a98a8b2e8ec8bd5577813de704.jpg, createdBy=29fc2176768, createdName=祝您健康, createdTime=Sat Apr 28 09:10:16 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262340, encodeId=7cc112623404d, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275698, encodeId=065412e5698fb, content=<a href='/topic/show?id=aad38494640' target=_blank style='color:#2F92EE;'>#脑瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84946, encryptionId=aad38494640, topicName=脑瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279254, encodeId=637812e9254a2, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Apr 13 10:11:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304853, encodeId=a9be304853d7, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Wed Apr 11 19:29:11 CST 2018, time=2018-04-11, status=1, ipAttribution=)]
    2018-04-11 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

相关资讯

JAMA:献血后,要不要补铁?

众所周知,少量献血后是不需要采取什么特殊的药物来快速促进人体造血,人体正常的代偿就会缓慢恢复献血时所失去的血量,并能完全恢复能献血前水平,只是因体质不同,恢复时间快慢不同而已。如果献血后口服铁剂,又会发生什么?JAMA杂志2月16日刊登了一篇文章阐述献血后口服铁剂补铁的益处。首先研究者提出研究的背景:基于在美国允许的两次献血间隔的时间差最小是8周,但是血红蛋白的恢复(恢复到目前普遍接受的标准线12

Diabetes Care:铁代谢的生化标志物与2型糖尿病的关系

  有观察性研究发现铁蛋白和2型糖尿病有关,机体较高的铁储备可能参与了2型糖尿病的发展。然而铁蛋白不会被铁储备所影响,因此相对于其他标志物,铁蛋白并不能完全反映机体的铁代谢情况。研究人员通过观察铁蛋白、转铁蛋白饱和度(TSAT)、血清铁和转铁蛋白与2型糖尿病的发生,研究铁在2型糖尿病发病机制中的作用。  欧洲癌症与营养前瞻性调查(EPIC- InterAct)研究中对已明确诊断

Blood:铁蛋白是通过两条独特的非经典囊泡途径分泌。

铁蛋白的转运在组织铁代谢过程中发挥主要作用,铁蛋白功能异常与铁平衡紊乱和神经退行性疾病相关。在大部分真核生物中,铁蛋白位于胞内,以非毒性、非活性形式储存铁。对于昆虫,铁蛋白为分泌蛋白,在铁的系统分布调节中发挥主要作用。哺乳动物缺乏调控经典高尔基分泌铁蛋白的信号肽,但在血清中发现,铁蛋白是通过非经典的溶酶体分泌途径分泌。

Biochim Biophys Acta:母乳也成抗癌利器?新研究开启乳铁蛋白“杀手”模式

在一项由奥地利科学基金(FWF)资助的项目中,奥地利格拉茨大学的科学家们对母乳中的某种宿主防御肽进行了改造,使其能够特异性识别并攻击癌细胞。这种存在于多种哺乳动物母乳中的活性大分子可以诱导细胞凋亡,具有潜在的癌症治疗价值。

Cell:铁蛋白维持机体血糖促进对于败血症的耐受性

这项研究,为研究机体如何调节代谢来适应和忍受败血症的后果提供了新的理论基础。并且揭示了铁蛋白对于败血症的保护作用,补充铁蛋白很有可能成为未来治疗败血症的潜力手段。

Nat Commun:铁蛋白和老年痴呆有关系?!

近日,一篇发表于国际杂志Nature Communications上的研究论文中,来自墨尔本大学的一项研究表明,高水平的铁蛋白或许和个体轻度认知损伤向阿尔兹海默氏症过渡直接相关。文章中研究人员对91名认知正常的个体、144有轻度认知损伤的个体及67名阿尔兹海默氏症个体进行了长达7年的研究,研究结果显示,在那些轻度认知损伤个体的脑脊髓液中较高水平的铁蛋白或许和其向阿尔兹海默氏症转换直接相关,而铁蛋白